OPKO HEALTH, INC. reported the three months ended March 31, 2026 results: revenue $124.2 million, net income $54.8 million, EPS $0.07 per share.
“each is responsible for 50% of the program's development costs. First Quarter Financial Results • Consolidated: Consolidated total revenues for the first quarter of 2026 were $124.2 million compared with $149.9 million for the 2025 period, with the decrease principally resulting from the sale of certain BioReference assets in 2025. Operating loss for the first”
Earnings Releases
OPKO HEALTH, INC. reported three months ended March 31, 2024 results: revenue $173.7 million, net income $81.8 million, or $0.12 per share, EPS $0.12 per share.
“was $34.4 million in the first quarter of 2024 compared with $40.0 million in the 2023 period. ● Consolidated: Consolidated total revenues for the first quarter of 2024 were $173.7 million compared with $237.6 million for the comparable period of 2023. Operating loss for the first quarter of 2024 increased to $71.5 million from $30.6 million for the 2023 quarter,”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.